Accelerating Biomarker Discovery with Multi-Agent AI

AstraZeneca shares how the company is applying multi-agent AI and foundation models to accelerate biomarker discovery, drive reproducible science, and reshape the way oncology research teams work. From FAIR data to FAIR science, the talk explores how automation, intelligent workflows, and human-centered tools are transforming R&D across the drug development lifecycle.

Key Takeaways:

1. AI agents are augmenting scientists by breaking down complex questions and automating repeatable tasks to accelerate insight generation.
2. FAIR data is only the beginning; AstraZeneca is building toward FAIR science with reusable workflows and traceable outputs.
3. Personalization is built into the system, with interfaces and responses tailored to the needs of scientists, executives, and other stakeholders.